CMR Myocardial Tissue Based Prediction of Ischemic MR Revascularization Response

基于 CMR 心肌组织的缺血 MR 血运重建反应预测

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Mitral regurgitation (MR) is present in one in five coronary artery disease (CAD) patients undergoing revascularization, conferring markedly increased morbidity and mortality. In prior research by our group and others, MR in patients with CAD has been strongly linked to ischemia and infarction in myocardium underlying the mitral valve. Ischemia can be reversed with revascularization, whereas infarction cannot. However, in clinical practice, MR response to revascularization is poorly understood. In nearly half of patients, MR improves with surgical or percutaneous coronary revascularization alone - in the remainder MR persists or worsens. Uncer- tainty as to which patients with MR will respond to revascularization alone limits the ability to optimize therapy. Cardiac magnetic resonance (CMR) imaging is a powerful tool to identity ischemia and infarction, as well as function and geometry. CMR tissue characterization is known to predict revascularization-induced improvement in LV function and remodeling, but has never before been tested as a planning tool for MR. Our central hypothesis is that MR response to revascularization can be predicted prior to therapy via CMR, with MR improvement dependent on presence and magnitude of ischemia in viable (alive) myocardium supporting the mitral valve. Additionally, we hypothesize that non-ischemic fibrosis in patients with CAD is associated with persistent MR after revascularization, attributable to adverse global myocardial remodeling that blunts the ability of the mitral valve to respond to revascularization. To test these hypotheses, we will study at least 156 CAD patients with advanced (≥moderate) MR undergoing coronary revascularization alone. Stress perfusion CMR will be performed pre and post-revascularization to assess baseline myocardial tissue properties and revascularization induced change in ischemia. Echocardiography (pre, 3, and 6 months post) will be the reference for MR, so as to apply a well-validated standard concordant with prior NIH studies and widespread clinical practice. Aim 1 will compare presence and magnitude of ischemia and infarction between patients with and without improved MR. Aim 2 will compare non-ischemic fibrosis between groups, including focal mid-wall fibrosis and global extracellular volume. Aim 3 will develop predictive models for MR response to revascularization, using both primary CMR data and finite element modeling. Our track record in CMR, echocardiography, mitral valve physiology, and computational modeling makes us uniquely poised to address these issues. The novel information to be gained from this research will enable development of predictive models to differentiate a priori those patients in whom MR will improve with revascularization alone from those in whom MR will persist (thereby warranting ancillary interventions to treat MR and potentially avoid its long term clinical consequences). Results will provide key foundational insights concerning MR physiology, and thus will inform the design of future research focused on optimization of established and emerging therapeutic strategies to treat MR in patients unresponsive to revascularization alone.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jonathan W. Weinsaft其他文献

INCIDENTAL DETECTION OF LEFT VENTRICULAR THROMBUS BY ROUTINE ECHOCARDIOGRAPHY: INSIGHTS INTO PERFORMANCE CHARACTERISTICS USING DELAYED ENHANCEMENT (DE) CMR
  • DOI:
    10.1016/s0735-1097(11)60784-5
  • 发表时间:
    2011-04-05
  • 期刊:
  • 影响因子:
  • 作者:
    Jonathan W. Weinsaft;Han W. Kim;Anna L. Crowley;Igor Klem;Chetan Shenoy;Debbie W. Chen;Rhoda Brosnan;Dipan J. Shah;Eric J. Velazquez;Michele Parker;Robert M. Judd;Raymond J. Kim
  • 通讯作者:
    Raymond J. Kim
Prognostic significance of the right ventricular to left ventricular volume ratio in pulmonary hypertension: A multimodality validation study
右心室与左心室容积比在肺动脉高压中的预后意义:一项多模态验证研究
  • DOI:
    10.1016/j.jocmr.2024.101303
  • 发表时间:
    2025-03-01
  • 期刊:
  • 影响因子:
    6.100
  • 作者:
    Giorgia Falco;Lily Jin;Robert S. Zhang;Nil Rawal;Mahniz Reza;Jiahao Li;Pablo Villar-Calle;Zachary Falk;Annie Tsay;Andre T. Cheng;Pascal Spincemaille;Jonathan W. Weinsaft;Jiwon Kim
  • 通讯作者:
    Jiwon Kim
Incremental yield of stress perfusion cardiac magnetic resonance over exercise stress echocardiography for detection of myocardial injury in hodgkin lymphoma survivors - A prospective multimodality imaging study
压力灌注心脏磁共振与运动应激超声心动图检测霍奇金淋巴瘤幸存者心肌损伤的增量收益——一项前瞻性多模态成像研究
  • DOI:
    10.1016/j.jocmr.2024.101287
  • 发表时间:
    2025-03-01
  • 期刊:
  • 影响因子:
    6.100
  • 作者:
    Annie Tsay;Matthew Matasar;Chaya S. Moskowitz;Jessica Scott;Kevin C. Oeffinger;Anthony F. Yu;Jiwon Kim;Lily Jin;Mahniz Reza;Jennifer E. Liu;Jonathan W. Weinsaft
  • 通讯作者:
    Jonathan W. Weinsaft
Delayed cardiac perforation of the Durata implantable cardioverter-defibrillator lead more than 1 year after implantation
  • DOI:
    10.1016/j.hrcr.2016.04.005
  • 发表时间:
    2016-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Sandeep K. Sharma;Jonathan W. Weinsaft;James E. Ip;Jim W. Cheung
  • 通讯作者:
    Jim W. Cheung
GENDER DISPARITIES IN COVID-19 SURVIVORS WITH IMPAIRED QUALITY OF LIFE, EFFORT TOLERANCE AND CARDIOPULMONARY SYMPTOMS - A PROSPECTIVE MULTICENTER STUDY
  • DOI:
    10.1016/s0735-1097(24)04445-0
  • 发表时间:
    2024-04-02
  • 期刊:
  • 影响因子:
  • 作者:
    Krista Zachariah;Dustin Wessells;Mahniz Reza;Caitlin Chiu;Alexander Volodarskiy;Evelyn M. Horn;Prianca Tawde;Parag Goyal;Jonathan W. Weinsaft;Jiwon Kim
  • 通讯作者:
    Jiwon Kim

Jonathan W. Weinsaft的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jonathan W. Weinsaft', 18)}}的其他基金

Delayed Enhancement MRI for Detection of Sub-Clinical Papillary Muscle Infarction
延迟增强 MRI 检测亚临床乳头肌梗塞
  • 批准号:
    8677953
  • 财政年份:
    2010
  • 资助金额:
    $ 76.47万
  • 项目类别:
Delayed Enhancement MRI for Detection of Sub-Clinical Papillary Muscle Infarction
延迟增强 MRI 检测亚临床乳头肌梗塞
  • 批准号:
    8131661
  • 财政年份:
    2010
  • 资助金额:
    $ 76.47万
  • 项目类别:
Delayed Enhancement MRI for Detection of Sub-Clinical Papillary Muscle Infarction
延迟增强 MRI 检测亚临床乳头肌梗塞
  • 批准号:
    8471755
  • 财政年份:
    2010
  • 资助金额:
    $ 76.47万
  • 项目类别:
Delayed Enhancement MRI for Detection of Sub-Clinical Papillary Muscle Infarction
延迟增强 MRI 检测亚临床乳头肌梗塞
  • 批准号:
    8268552
  • 财政年份:
    2010
  • 资助金额:
    $ 76.47万
  • 项目类别:
Delayed Enhancement MRI for Detection of Sub-Clinical Papillary Muscle Infarction
延迟增强 MRI 检测亚临床乳头肌梗塞
  • 批准号:
    7872437
  • 财政年份:
    2010
  • 资助金额:
    $ 76.47万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 76.47万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 76.47万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 76.47万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 76.47万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 76.47万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 76.47万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 76.47万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 76.47万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 76.47万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 76.47万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了